Evidence map›Paper›PMID 29467739›Full record

ArticleFrontiers in microbiology2018

Epitope Mapping of

Marcelina Pyclik, Sabina Górska, Ewa Brzozowska, Anna Dobrut, Jarosław Ciekot, Andrzej Gamian, Monika Brzychczy-Włoch

Abstract read
In one paragraph

Article in Frontiers in microbiology, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.

0numbers the graph read from it
0cells of the map it votes in
13citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

13 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Detection of immunoreactive proteins ofFrontiers in cellular and infection microbiology · 2023
    Article
  7. Article
  8. Review
  9. Computational tools for modern vaccine development.Human vaccines & immunotherapeutics · 2020
    Review
  10. Article
  11. Article
  12. Epitopes of Immunoreactive Proteins ofFrontiers in cellular and infection microbiology · 2018
    Article
  13. EF-Tu From Non-typeableFrontiers in immunology · 2018
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Marcelina PyclikLudwik Hirszfeld Institute of Immunology and Experimental Therapy, Polish Academy of Sciences, Wroclaw, Poland.
Sabina GórskaLudwik Hirszfeld Institute of Immunology and Experimental Therapy, Polish Academy of Sciences, Wroclaw, Poland.
Ewa BrzozowskaLudwik Hirszfeld Institute of Immunology and Experimental Therapy, Polish Academy of Sciences, Wroclaw, Poland.
Anna DobrutChair of Microbiology, Department of Molecular Medical Microbiology, Jagiellonian University Medical College, Krakow, Poland.
Jarosław CiekotLudwik Hirszfeld Institute of Immunology and Experimental Therapy, Polish Academy of Sciences, Wroclaw, Poland.
Andrzej GamianLudwik Hirszfeld Institute of Immunology and Experimental Therapy, Polish Academy of Sciences, Wroclaw, Poland.
Monika Brzychczy-WłochChair of Microbiology, Department of Molecular Medical Microbiology, Jagiellonian University Medical College, Krakow, Poland.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The elongation factor Tu has been identified as one of the most immunoreactive proteins that was recognized by human sera of GBS (group B streptococcus) positive patients. In this paper, we present the polypeptide-specific epitopes of the bacterial protein that are recognized by human antibodies:

Indexed as

ELISAelongation factor Tuepitope mappinggroup B streptococcusPEPSCANStreptococcus agalactiaesynthetic peptidevaccination

Identifiers

PMID29467739
PMCPMC5808131

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.